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 Conclusions 
A. Side chain charges and/or N-methylation are not essential for in vitro affinity and activity 
B. Significant influx into the mouse brain for peptide 1, 2 and 13 demonstrated by the Kin values and 
the parenchyma fraction 
C. The CACO-2 test predict a limited transport through the intestinal membrane (GI → blood). 
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Introduction Dmt1-DALDA and analogues 
The highly charged tetrapeptide Dmt-DALDA (Dmt-D-Arg-Phe-Lys-
NH2) has been previously identified as a potent μ-opioid receptor 
agonist and serves as a lead compound for the further development 
of novel therapeutic (peptidic) opioid analgesics.[1] Structural 
modifications of the peptide have been performed in order to 
determine the role of the side chain charges, N-methylation of the 
Phe3-Lys4 amide bond, and the influence of a benzazepine 
conformational constraint[2]  at the level of Phe3. 
 
All prepared compounds have been tested for their in vitro affinity 
and activity (GPI and MVD assays) and four of them for their in vivo 
tissue distribution and in vitro permeability (in- and efflux into and 
out of mouse brain and caco-2 test) 
Peptide GPI (IC50, nM) Rel.pot.* MVD (IC50, nM) Rel.pot.* MOR (IC50, nM) Rel.binding* DOR (IC50, nM) Rel.binding* 
H-Dmt-D-Arg-Phe-Lys-NH2 1 1.41 81 23.1 2.7 0.58  147  877  0.12  
H-Dmt-D-Arg-Phe-Nle-NH2 2 2.2  119 6.2  2.6 0.23  132.5  15.2  0.64  
H-Dmt-D-Cit-Phe-Lys-NH2 3 0.31  791 1.4  9.64 0.57  52.4  50.0  0.25  
H-Dmt-D-Cit-Phe-Nle-NH2 4 
 
0.89  203 4.7  4.12 0.79  28.1  3.98  1.46  
H-Dmt-D-Arg-Phe-NMeLys-NH2 5 8.3  106 7.0  6.0 0.26  115.4  309  0.027  
H-Dmt-D-Arg-Phe-NMeNle-NH2 6 4.35  45 1.5  9.3 0.26  135.8  16.0  0.51  
H-Dmt-D-Cit-Phe-NMeLys-NH2  7 1.01  398 4.4  9.5 0.94  23.6  39.2  0.347  
H-Dmt-D-Cit-Phe-NMeNle-NH2 8 
 
0.65  434 1.5  1.0 2.92  11.3  5.03 1.94 
H-Dmt-D-Arg-Aba-Lys-NH2 9 76.0  13  64  (IC25, max50%) 0.67 0.605  50.97  38.56  0.276  
H-Dmt-D-Arg-Aba-Nle-NH2 10 1.45  327 3.1  5 0.432  82.28  7.46  1.24  
H-Dmt-D-Cit-Aba-Lys-NH2 11 49.0 18.9 1000 30 % inh 2.618 8.547 56.91 0.108 
H-Dmt-D-Cit-Aba-Nle-NH2 12 
 
0.78 (IC35max : 67 %) 643 1.16 17.5 0.931 38.64 3.176 2.1816 
H-Dmt-D-Arg-Aba-Gly-NH2 13 0.32 / 0.42  / 0.15  / 0.60  / 
*relative to Leu5-enkephalin (binding : MOR: 29.9 nM, DOR: 9.77 nM) 
 
Activity : µ agonist and d agonist 
side-chain charges are not  
essential for in vitro activity 
the conformational constraint of the Phe 
residue by the Aba results in highly 
potent compounds, but is not 
compatible with the Lys side chain 
N-methylation is allowed for in vitro 
activity and potentially stabilizes the 
amide bond between Phe3 and Lys4 
Peptide 
Chem. Properties 
MW / Log P / Log D (7.4)/Log S  














639.8 / 0.4 / -0.4 / -6.6  
 264.6 / 10 / 8 /20 
<0.1 89 <0.1 95 
H-Dmt-D-Arg-Phe-Nle-NH2 2 
624.8 / 1.9 / 1.1 / -7.0  
 238.5 / 9 / 7 /19 
<0.4 101 <0.5 89 
H-Dmt-D-Cit-Phe-Lys-NH2 3 
640.8 / 0.4 / -0.4 / -7.4  
 257.8 / 9 / 8 /19 
<0.6 85 <0.8 111 







H-Dmt-D-Arg-Phe-Lys-NH2 1 0.37 ± 0.08 23.12 ± 10.26 76.88 ± 10.26 0.058 ± 0.11 
H-Dmt-D-Arg-Phe-Nle-NH2 2 0.25 ± 0.25 32.97 ± 9.99 67.03 ± 9.99 0.039 ± 0.11 
H-Dmt-D-Cit-Phe-Lys-NH2 3 -0.31 ± 0.45 19.39 ± 15.81 80.61 ± 15.81 0.027 ± 0.022 
H-Dmt-D-Arg-Aba-Gly-NH2 13 0.45 ± 0.20 30.95 ± 19.75 69.05 ± 19.75 0.096 ± 0.046 
Permeability 






















Relative concentrations in the different tissues : MTR experiment 
-Significative accumulation in liver for H-Dmt-D-Arg-Phe-Nle-NH2   2 
- No specific accumulation for the three others peptides 
13 
Superpotent µ/d agonist 
-Significant influx for peptide 1,2 and 13 
-No efflux for peptides 1 and 2, while statistically significant  
  efflux observed for 13 
the CACO-2 assay predicts a limited transport through the intestinal 
membrane 
